Prantae Solutions, a deep-tech company specializing in next-generation diagnostic innovations, has raised ₹5 crores in a seed funding round led by the IAN Group, with participation from investors IAN Alpha Fund, Samir Kalia, Deepank Kumar, and Nitin Zamre.
The funds raised will be used to launch complementary diagnostic solutions for kidney health and diabetes care, further enhancing Prantae’s product portfolio and research and development.
Sumona Karjee Mishra, Chairman & Managing Director, Prantae Solutions, said, “With the invaluable support of Indian Angel Network, we are empowered to accelerate our journey toward transforming healthcare. This investment fuels our vision to deliver world-class point-of-care diagnostics with our flagship product Proflo-U, and champion early detection and personalized kidney care. Together, we are creating a future where innovation meets compassion, redefining health outcomes for communities everywhere.”
Padmaja Ruparel, Co-founder, IAN Group, said, “Prantae Solutions is a stellar example of how deep-tech innovations can address critical healthcare challenges, especially in underserved markets. Their transformative diagnostic tools have the potential to make healthcare more inclusive and accessible, not just in India but globally. We are proud to back a team that combines exceptional innovation with a deeply personal mission to create meaningful impact.”
Founded in 2015 by Sumona Karjee Mishra and Aseem Mishra, Prantae leverages its point-of-care solutions to deliver accurate, timely, and actionable diagnostic tools to address chronic health conditions.
Their flagship product, Proflo-U, revolutionizes kidney health assessment with its globally unmatched detection range for microalbumin to proteinuria levels. Powered by proprietary nanosensors, IoT, and AI technology, Proflo-U offers calibration-free, cost-effective, and user-friendly testing solutions designed to improve patient outcomes and reduce healthcare costs.
